Department of Obstetrics, Gynecology and Reproductive Sciences, Kafkas University, Kars, Turkey.
Department of Obstetrics and Gynecology, School of Medicine, Firat University, Elazig, Turkey.
J Obstet Gynaecol. 2021 Feb;41(2):279-284. doi: 10.1080/01443615.2020.1758926. Epub 2020 Jul 1.
Asprosin and subfatin are recently discovered two new hormones of adipocyte origin that play a role in the regulation of glucose metabolism. Polycystic ovary syndrome (PCOS) is a gynaecological syndrome presenting with energy turbulence. The aim of this study was to investigate whether asprosin and subfatin play a role in PCOS disease. Thirty participants with a diagnosis of PCOS and thirty control group participants were included in this case-control study. Hormone profiles of the participants (subfatin, asprosin, insulin, prolactin, thyroid-stimulating hormone (TSH), oestradiol (E2), follicle-stimulating hormone (FSH), luteinising hormone (LH), dehydroepiandrosterone sulphate (DHEA-SO), lipid profiles [(total testosterone, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, cholesterol)], fasting blood sugar (FBS) and high-sensitivity C-reactive protein (hs-CRP) values were measured. While the levels of asprosin, LDL and triglyceride, TSH, E2, FSH, LH, DHEA-SO were found to be significantly higher in patients with PCOS compared to controls ( = .005; = .01), subfatin and HDL levels were found to be low. Significantly decreasing subfatin and increasing asprosin levels in circulation in PCOS may play a role in the etiopathology of this disease and that they may also be new candidate molecules in addition to classical laboratory parameters in the diagnosis and follow-up of PCOS in the future.Impact statement The studies investigating the relationship between PCOS and asprosin are contradictory. Although subfatin has been studied in many metabolic diseases, it has not been studied yet whether it is associated with PCOS. Furthermore, whether there is a mutual relationship between subfatin and asprosin in patients with PCOS has not been studied yet. This available data indicates that significantly decreasing subfatin and increasing asprosin levels in the circulation in PCOS may play a role in the etiopathology of this disease. The findings are promising in that decreasing subfatin and increasing asprosin levels will shed new light on reproductive endocrinology changes caused by PCOS and may help to clarify the pathophysiology of PCOS. Furthermore, in our study, the asprosin/subfatin ratio was above three in PCOS disease. This ratio reported here is anticipated to contribute to the course or follow-up of the disease in the future. Also, subfatin has been investigated here for the first time, may also be a new candidate molecule in addition to classical laboratory parameters in the diagnosis and follow-up of PCOS.
瘦素和亚瘦素是最近发现的两种源自脂肪细胞的新激素，它们在调节葡萄糖代谢中发挥作用。多囊卵巢综合征（PCOS）是一种表现为能量紊乱的妇科综合征。本研究旨在探讨瘦素和亚瘦素是否在 PCOS 疾病中发挥作用。本病例对照研究纳入了 30 名 PCOS 患者和 30 名对照组参与者。测量了参与者的激素谱（亚瘦素、瘦素、胰岛素、催乳素、促甲状腺激素（TSH）、雌二醇（E2）、卵泡刺激素（FSH）、黄体生成素（LH）、脱氢表雄酮硫酸盐（DHEA-SO）、血脂谱[总睾酮、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、甘油三酯、胆固醇]、空腹血糖（FBS）和高敏 C 反应蛋白（hs-CRP）值。结果显示，与对照组相比，PCOS 患者的瘦素、LDL 和甘油三酯、TSH、E2、FSH、LH、DHEA-SO 水平显著升高（=0.005；=0.01），而亚瘦素和 HDL 水平较低。PCOS 患者循环中瘦素和亚瘦素水平的显著降低和瘦素水平的升高可能在该疾病的发病机制中发挥作用，并且它们也可能是除经典实验室参数外，未来 PCOS 诊断和随访的新候选分子。
研究 PCOS 和瘦素之间关系的研究结果相互矛盾。尽管亚瘦素已在许多代谢疾病中进行了研究，但尚未研究其是否与 PCOS 相关。此外，PCOS 患者中亚瘦素和瘦素之间是否存在相互关系尚未研究。这些现有数据表明，PCOS 患者循环中瘦素和亚瘦素水平的显著降低和瘦素水平的升高可能在该疾病的发病机制中发挥作用。这些发现很有前景，因为降低瘦素和升高瘦素水平将为 PCOS 引起的生殖内分泌变化提供新的见解，并有助于阐明 PCOS 的病理生理学。此外，在我们的研究中，PCOS 疾病中的瘦素/亚瘦素比值高于 3。这里报道的这个比值预计将有助于未来疾病的进程或随访。此外，亚瘦素是首次在这里进行研究，除了经典的实验室参数外，它也可能是 PCOS 诊断和随访的新候选分子。
